No-one should die of Histiocytosis

Our research programmes provide a beacon of hope for the many children and adults battling Histiocytosis, to ensure this research continues we ask you to pledge your support.

Langerhans Cell Histiocytosis - Adults

previously known as Histiocytosis X

pdf1Management of Adult Patients with LCH.pdf


Dif­fe­rent working groups ha­ve re­view­ed avail­able in­ter­na­tio­nal and na­tio­nal gui­de­lines and re­com­men­da­ti­ons for dia­gno­sis, tre­at­ment and fol­low-up of LCH. A syn­the­sis of this in­for­ma­ti­on was ge­ne­ra­ted and publis­hed af­ter ap­pro­val of ma­ny in­vol­ved spe­cia­lists and is available from the EURO-Histio-Net website linked in the following LCH pages.

· Lan­ger­hans Cell His­tio­cy­to­sis (LCH) – Adults
Re­com­men­da­ti­ons for dia­gno­sis, cli­ni­cal work-up and treatment of adults; Ver­si­on 1, Au­gust 2013

The Guidelines include:
· Back­ground, Pro­cess of De­ve­lop­ment and Re­stric­tions
The­re are no uni­ver­sal­ly ac­cep­ted in­ter­na­tio­nal gui­de­lines avail­able for the dia­gno­sis and tre­at­ment of adult LCH pa­ti­ents.
· Ge­ne­ral con­s­ide­ra­ti­on
· Dia­gno­sis
De­fi­ni­ti­ve dia­gno­sis of LCH re­qui­res clas­si­cal his­topa­tho­lo­gy con­fir­med by de­mons­tra­ti­on of CD1a or Lan­ge­rin (CD207) or by the ul­tra­struc­tu­ral pre­sence of Bir­beck gra­nu­les.

· Pre­tre­at­ment cli­ni­cal eva­lua­ti­on
Histo­ry and phy­si­cal ex­ami­na­ti­on
La­bo­rato­ry and ra­dio­gra­phic eva­lua­ti­on
Fur­ther in­ves­ti­ga­ti­ons for spe­ci­fic cli­ni­cal sce­na­ri­os

· Or­gan in­vol­ve­ment
Af­ter the dia­gno­sis of LCH has be­en ma­de, in­vol­ve­ment of other or­gans should be eva­lua­ted and de­fi­ned ac­cor­ding to the cli­ni­cal, bio­lo­gi­cal or ra­dio­lo­gi­cal cri­te­ria.

Stra­ti­fi­ca­ti­on / Cli­ni­cal clas­si­fi­ca­ti­on
Risk or­gans and spe­cial sites
En­do­cri­no­lo­gic dys­func­tion
Der­ma­to­lo­gi­cal in­vol­ve­ment
Gas­tro­in­tes­ti­nal in­vol­ve­ment

· Tre­at­ment

Tre­at­ment re­com­men­da­ti­ons are ba­sed on site and ex­ten­si­on of the di­sea­se.
Ma­nage­ment al­go­rithm
Care­ful ob­ser­va­ti­on, lo­cal or “mild sys­te­mic” the­ra­py
Sys­te­mic the­ra­py
Tre­at­ment op­ti­ons in ca­se of re­ac­tiva­ti­on
Tre­at­ment and hor­mone re­pla­ce­ment of en­do­cri­no­pa­thies
Cen­tral ner­vous sys­tem in­vol­ve­ment

· Pri­ma­ry pul­mon­a­ry LCH

Alt­hough the lungs may be af­fec­ted si­mul­ta­neo­us­ly with other or­gans an iso­la­ted pul­mon­a­ry LCH is ob­ser­ved mo­re fre­quent­ly and re­p­res­ents a spe­cial form of adult LCH.
Epi­de­mio­lo­gy and cli­ni­cal fea­tures
Tre­at­ment and pro­gno­sis

· Pre­g­nan­cy

· Fol­low-up

LCH may re­ac­tiva­te and lead to chro­nic lo­cal sym­ptoms or in­du­ce or­gan dys­func­tion. Ra­re­ly LCH is as­so­cia­ted with ma­li­gnant tu­mors. The­re­fo­re, fol­low-up in­ves­ti­ga­ti­ons of di­sea­se and mo­ni­to­ring of func­tio­nal im­pair­ments are ne­cessa­ry.

Our thanks to all of our Histio Partners for their input to these pages.


Your support is vital to ensure that we can continue to deliver our Research and Information Programs. Thank you.